Tag Archives: biotechnology law

Sanofi-Aventis v. Pfizer – Possession and Appreciation Trump Structure

Posted on November 6, 2013 by Warren Woessner

On Tuesday, the Fed. Cir. affirmed a finding by the Board that Pfizer was entitled to an earlier priority date for a claim to  cDNA encoding the IL-13 receptor protein (Sanofi-Aventis v. Pfizer, Inc., App. No. 2012-1345 (Fed. Cir. November … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , , , , | Leave a comment

Novozymes Loses “Possession” Of Its Enzyme

Posted on November 1, 2013 by Warren Woessner

I am not sure how I missed this decision, which came down on July 22nd, but it offers a rather scary hi-def picture as to where the written description requirement of s. 112 has been and where it is headed. … Continue reading →

Posted in Written Description Requirements (WDR) | Tagged , , , , , , , , | 1 Comment

EPO Abolishes Prior “Short” Divisional Guidelines

Posted on October 21, 2013 by Warren Woessner

This is a guest post from Mewburn Ellis of London. The Administrative Council (the governing body of the European Patent Office) has decided at its meeting on 16 October 2013 to change the regulations regarding the deadline for filing divisional … Continue reading →

Posted in EP and UK Practice | Tagged , , , , , , | Leave a comment

In Memoriam: Howard W. Bremer

Posted on October 17, 2013 by Warren Woessner

Howard W. Bremer passed away on Friday, ending a long career at the Wisconsin Alumni Research Foundation, where he served as Patent Counsel for 28 years, and continued with emeritus status thereafter. He also was one of the founders of … Continue reading →

Posted in People | Tagged , , , , , | 3 Comments